Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib and Pembrolizumab in Advanced Uveal Melanoma
NCT05524935Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Oct 2022
- Primary completion
- Jul 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, pembrolizumab in Uveal melanoma (UM), sponsored by Moffitt Cancer Center. Started Oct 2022; status: active, not recruiting.
02
Drugs
olaparibpembrolizumab
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT05524935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05524935.